What is Ranomics?
Ranomics operates at the intersection of advanced cell and protein engineering, providing critical infrastructure for the biotechnology and life sciences industries. The company distinguishes itself through the development of custom DNA variant libraries and high-throughput screening capabilities, which are essential for modern biologic development. By leveraging a team of Ph.D.-level experts, Ranomics has successfully facilitated over 100 projects, enabling partners to achieve greater precision and speed in their scientific workflows. Their market position is defined by a commitment to technical excellence and the ability to solve complex biological challenges that traditional R&D methods often struggle to address.
How much funding has Ranomics raised?
Ranomics has raised a total of $2.8M across 2 funding rounds:
Angel/Seed
$1.2M
Angel/Seed
$1.6M
Angel/Seed (2016): $1.2M, investors not publicly disclosed
Angel/Seed (2016): $1.6M, investors not publicly disclosed
Key Investors in Ranomics
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Ranomics?
With this recent capital infusion, Ranomics is poised to transition from its foundational development phase into a period of aggressive operational scaling. The strategic roadmap likely involves expanding the capacity of their high-throughput screening facilities and deepening their service offerings for enterprise-level biotechnology clients. As the demand for sophisticated protein engineering continues to rise, the company is expected to leverage its current momentum to secure further market share, potentially exploring new therapeutic areas or enhancing its proprietary technology stack to maintain a competitive edge in the global life sciences ecosystem.
See full Ranomics company page
